Long-term outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a 15-year national referral centre experience
By: Rok Petric and Gasper Pilko
References
- Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology 2017; 71: 847–58. doi: 10.1111/his.13324
- Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 2008; 98: 277–82. doi: 10.1002/jso.21054
- Sugarbaker PH, Ronnett BM, Archer A, Averbach AM, Bland R, Chang D, et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996; 30: 233–80. PMID: 8960339
- Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to pseudomyxoma peritonei. Am J Surg Pathol 1995; 19: 1390–408. doi: 10.1097/00000478-199512000-00006
- Smeenk RM, van Velthuysen MLF, Verwaal VJ, Zoetmulder FAN. Appendiceal neoplasms and pseudomyxoma peritonei: a population-based study. Eur J Surg Oncol 2008; 34: 196–201. doi: 10.1016/j.ejso.2007.04.002
- Patrick-Brown TDJH, Carr NJ, Swanson DM, Larsen S, Mohamed F, Flatmark K. Estimating the prevalence of pseudomyxoma peritonei in Europe using a novel statistical method. Ann Surg Oncol 2021; 28: 252–7. doi: 10.1245/s10434-020-08655-8
- Gough DB, Donohue JH, Schutt AJ, Gonchoroff NJ, Goellner JR, Wilson TO, et al. Pseudomyxoma peritonei: long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219: 112–9. doi: 10.1097/00000658-199402000-00002
- Sugarbaker PH. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27: 239–43. doi: 10.1053/ejso.2000.1038
- Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol 2019; 10: 3–23. doi: 10.1007/s13193-018-0856-1
- Elias D, Gilly F, Quenet F, Bereder JM, Sideris L, Mansvelt B, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010; 36: 456–62. doi: 10.1016/j.ejso.2010.01.006.
- Deraco M, Kusamura S, Laterza B, Favaro M, Fumagalli L, Costanzo P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. In Vivo 2006; 20(6A): 773–6. PMID: 17203766
- Santullo F, Pacelli F, Abatini C, El Halabieh MA, Fortunato G, Lodoli C, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy for pseudo-myxoma peritonei of appendiceal origin: a single-center experience. Front Surg 2021; 8: 715119. doi: 10.3389/fsurg.2021.715119.
- Narasimhan V, Wilson K, Britto M, Warrier S, Lynch AC, Michael M, et al. Outcomes following cytoreduction and HIPEC for pseudomyxoma peritonei: 10-year experience. J Gastrointest Surg 2020; 24: 899–906. doi: 10.1007/s11605-019-04239-4
- McBride KE, McFadden DW, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Res 2013; 183: 246–52. doi: 10.1016/j.jss.2012.12.040
- Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30: 2449–56. doi: 10.1200/JCO.2011.39.7166
- Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol 2021; 47: 11–35. doi: 10.1016/j.ejso.2020.02.012
- Pilko G, Petric R. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a single institution experience. Radiol Oncol 2026; 60: 436–41. doi: 10.2478/raon-2026-0041
- Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6: 727–31. doi: 10.1007/s10434-999-0727-7
- Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Cancer Treat Res. Vol. 82. Boston: Kluwer Academic Publishers; 1996. p. 359–74. doi: 10.1007/978-1-4613-1247-5_23
- Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29–42. doi: 10.1097/00000658-199501000-00004
- Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–13. doi: 10.1097/01.sla.0000133083.54934.ae
- Bartlett DL. HIPEC: the complexities of clinical trials. Ann Surg Oncol 2008; 15: 1277–9. doi: 10.1245/s10434-008-9863-4.
- Mittal R, Chandramohan A, Moran BJ. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia 2017; 33: 511–9. doi: 10.1080/02656736.2017.1310938
- Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg 2021; 156: e206363. doi: 10.1001/jamasurg.2020.6363.
- Kusamura S, Hutanu I, Baratti D, Deraco M. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei. J Surg Oncol 2013; 108: 1–8. doi: 10.1002/jso.23329
- Lopes A, de Mello ES, Mendoza Lopez RV, Leonardi PC, Ribeiro U. Prognostic impact of pathology, cytoreduction and tumor markers in pseudomyxoma peritonei. J Surg Res 2022; 274: 68–76. doi: 10.1016/j.jss.2022.01.001
- Wang B, Ma R, Rao B, Xu H. Serum and ascites tumor markers in the diagnostic and prognostic prediction for appendiceal pseudomyxoma peritonei. BMC Cancer 2023; 23: 90. doi: 10.1186/s12885-023-10545-7
- Yamaguchi T, Murata K, Shiota T, Takeyama H, Noura S, Sakamoto K, et al. Clinicopathological characteristics of low-grade appendiceal mucinous neoplasm. Dig Surg 2021; 38: 222–9. doi: 10.1159/000513973
- Blaj S, Dora D, Lohinai Z, Herold Z, Szasz AM, Herzberg J, et al. Prognostic factors in pseudomyxoma peritonei with emphasis on the predictive role of Peritoneal Cancer Index and tumor markers. Cancers (Basel) 2023; 15: 1326. doi: 10.3390/cancers15041326
- Enblad M, Cashin P, Ghanipour L, Graf W. Patterns of preoperative tumor markers can predict resectability and prognosis of peritoneal metastases: a clustering analysis. Ann Surg Oncol 2025; 32: 3638–47. doi: 10.1245/s10434-024-16860-y
- Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M. Validation of the recent PSOGI pathological classification of pseudomyxoma peritonei in a single-center series of 265 patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2018; 25: 404–13. doi: 10.1245/s10434-017-6252-1
- Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol 2015; 41: 396–9. doi: 10.1016/j.ejso.2014.08.476
- Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum 2011; 54: 293–9. doi: 10.1007/DCR.0b013e318202f026
Language: English
Submitted on: Jul 2, 2026
Accepted on: Aug 28, 2026
Published on: Oct 22, 2026
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2026 Rok Petric, Gasper Pilko, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.